Tirzepatide improves outcomes in patients with obesity-related HFpEF regardless of the severity of their baseline BMI or fat ...

Baseline BMI may play a significant role in improving exercise capacity, body weight and BP among patients with HF with ...

Obesity has become a global epidemic, contributing to a host of chronic health conditions such as type 2 diabetes, hypertension, and cardiovascular disease.

Pennington Biomedical researchers and their collaborators observed decreased activity in the brain regions responsible for ...

A retrospective cohort study found that semaglutide and tirzepatide are linked with significantly lower risks of dementia and ...

The U.S. Food & Drug Administration (FDA) has approved certain GLP-1 drugs for commercialization and use, including liraglutide ...

Eli Lilly outpaces Novo in the GLP-1 market with Tirzepatide and emerging blockbusters, signaling future growth. Read more on ...

While many believe the agents to be potential game changers, evidence is still lacking in psoriatic disease, and experts urge ...

Patients regain weight after stopping weight loss drugs, long-term success may depend on lifestyle and drug choice.

Loss per share was $(0.58), falling short of analyst expectations by $(0.13), or 29.1% (GAAP, Q2 2025). - Research and development expenses rose to $60.2 million in Q2 2025, up from $23.8 million in ...